Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Detection of Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis Using the Quantamatrix Multiplexed Assay Platform System

  • Wang, Hye-young (Optipharm, Inc., Wonju Eco Environmental Technology Center) ;
  • Uh, Young (Department of Laboratory Medicine, Yonsei University Wonju College of Medicine) ;
  • Kim, Seoyong (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Cho, Eunjin (Department of Microbiology, International Tuberculosis Research Center) ;
  • Lee, Jong Seok (Department of Microbiology, International Tuberculosis Research Center) ;
  • Lee, Hyeyoung (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University)
  • Received : 2017.08.04
  • Accepted : 2018.07.04
  • Published : 2018.11.01
⟨ Previous Next ⟩

Abstract

Background: The increasing prevalence of drug-resistant tuberculosis (TB) infection represents a global public health emergency. We evaluated the usefulness of a newly developed multiplexed, bead-based bioassay (Quantamatrix Multiplexed Assay Platform [QMAP], QuantaMatrix, Seoul, Korea) to rapidly identify the Mycobacterium tuberculosis complex (MTBC) and detect rifampicin (RIF) and isoniazid (INH) resistance-associated mutations. Methods: A total of 200 clinical isolates from respiratory samples were used. Phenotypic anti-TB drug susceptibility testing (DST) results were compared with those of the QMAP system, reverse blot hybridization (REBA) MTB-MDR assay, and gene sequencing analysis. Results: Compared with the phenotypic DST results, the sensitivity and specificity of the QMAP system were 96.4% (106/110; 95% confidence interval [CI] 0.9072-0.9888) and 80.0% (72/90; 95% CI 0.7052-0.8705), respectively, for RIF resistance and 75.0% (108/144; 95% CI 0.6731-0.8139) and 96.4% (54/56; 95% CI 0.8718-0.9972), respectively, for INH resistance. The agreement rates between the QMAP system and REBA MTB-MDR assay for RIF and INH resistance detection were 97.6% (121/124; 95% CI 0.9282-0.9949) and 99.1% (109/110; 95% CI 0.9453-1.0000), respectively. Comparison between the QMAP system and gene sequencing analysis showed an overall agreement of 100% for RIF resistance (110/110; 95% CI 0.9711-1.0000) and INH resistance (124/124; 95% CI 0.9743-1.0000). Conclusions: The QMAP system may serve as a useful screening method for identifying and accurately discriminating MTBC from non-tuberculous mycobacteria, as well as determining RIF- and INH-resistant MTB strains.

Keywords

Acknowledgement

Supported by : Korea Health Industry Development Institute (KHIDI)

References

  1. Zaman K. Tuberculosis: a global health problem. J Health Popul Nutr 2010;28:111-3.
  2. Bae E, Im JH, Kim SW, Yoon NS, Sung H, Kim MN, et al. Evaluation of combination of BACTEC mycobacteria growth indicator tube 960 system and Ogawa media for mycobacterial culture. Korean J Lab Med 2008;28:299-306. https://doi.org/10.3343/kjlm.2008.28.4.299
  3. Parsons LM, Somoskovi A, Gutierrez C, Lee E, Paramasivan CN, Abimiku A, et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev 2011;24:314-50. https://doi.org/10.1128/CMR.00059-10
  4. Rageade F, Picot N, Blanc-Michaud A, Chatellier S, Mirande C, Fortin E, et al. Performance of solid and liquid culture media for the detection of Mycobacterium tuberculosis in clinical materials: meta-analysis of recent studies. Eur J Clin Microbiol Infect Dis 2014;33:867-70. https://doi.org/10.1007/s10096-014-2105-z
  5. Blakemore R, Story E, Helb D, Kop J, Banada P, Owens MR, et al. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol 2010;48:2495-501. https://doi.org/10.1128/JCM.00128-10
  6. Skenders GK, Holtz TH, Riekstina V, Leimane V. Implementation of the INNO-LiPA Rif. $TB^{(R)}$ line-probe assay in rapid detection of multidrug-resistant tuberculosis in Latvia. Int J Tuberc Lung Dis 2011;15:1546-52. https://doi.org/10.5588/ijtld.11.0067
  7. Teo J, Jureen R, Chiang D, Chan D, Lin R. Comparison of two nucleic acid amplification assays, the Xpert MTB/RIF assay and the amplified Mycobacterium Tuberculosis Direct assay, for detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens. J Clin Microbiol 2011;49:3659-62. https://doi.org/10.1128/JCM.00211-11
  8. Singhal R, Myneedu VP, Arora J, Singh N, Sah GC, Sarin R. Detection of multi-drug resistance & characterization of mutations in tuberculosis isolates from North-Eastern States of India using GenoType MTBDRplus assay. Indian J Med Res 2014;140:501-6.
  9. Sharma SK, Kohli M, Yadav RN, Chaubey J, Bhasin D, Sreenivas V, et al. Evaluating the diagnostic accuracy of Xpert MTB/RIF assay in pulmonary tuberculosis. PLoS One 2015;10:e0141011. https://doi.org/10.1371/journal.pone.0141011
  10. Rahman A, Sahrin M, Afrin S, Earley K, Ahmed S, Rahman SM, et al. Comparison of Xpert MTB/RIF assay and GenoType MTBDRplus DNA probes for detection of mutations associated with rifampicin resistance in Mycobacterium tuberculosis. PLoS One 2016;11:e0152694. https://doi.org/10.1371/journal.pone.0152694
  11. Seifert M, Ajbani K, Georghiou SB, Catanzaro D, Rodrigues C, Crudu V, et al. A performance evaluation of MTBDRplus version 2 for the diagnosis of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2016;20: 631-7. https://doi.org/10.5588/ijtld.15.0788
  12. Kim LN, Kim M, Jung K, Bae HJ, Jang J, Jung Y, et al. Shape-encoded silica microparticles for multiplexed bioassays. Chem Commun (Camb) 2015;51:12130-3. https://doi.org/10.1039/C5CC02048D
  13. Wang HY, Uh Y, Kim S, Lee H. Performance of the Quantamatrix Multiplexed Assay Platform system for the differentiation and identification of Mycobacterium species. J Med Microbiol 2017;66:777-87. https://doi.org/10.1099/jmm.0.000495
  14. Wang HY, Uh Y, Kim S, Lee H. Quantamatrix Multiplexed Assay Platform system for direct detection of bacteria and antibiotic resistance determinants in positive blood culture bottles. Clin Microbiol Infect 2017;23:333.e1-7. https://doi.org/10.1016/j.cmi.2016.12.013
  15. Abbadi SH, Sameaa GA, Morlock G, Cooksey RC. Molecular identification of mutations associated with anti-tuberculosis drug resistance among strains of Mycobacterium tuberculosis. Int J Infect Dis 2009;13: 673-78. https://doi.org/10.1016/j.ijid.2008.10.006
  16. Tessema B, Beer J, Emmrich F, Sack U, Rodloff AC. Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia. BMC Infect Dis 2012;12:37. https://doi.org/10.1186/1471-2334-12-37
  17. Luo T, Zhao M, Li X, Xu P, Gui X, Pickerill S, et al. Selection of mutations to detect multidrug-resistant Mycobacterium tuberculosis strains in Shanghai, China. Antimicrob Agents Chemother 2010;54:1075-81. https://doi.org/10.1128/AAC.00964-09
  18. Slayden RA and Barry CE 3rd. The genetics and biochemistry of isoniazid resistance in Mycobacterium tuberculosis. Microbes Infect 2000;2: 659-69. https://doi.org/10.1016/S1286-4579(00)00359-2
  19. Jin J, Zhang Y, Fan X, Diao N, Shao L, Wang F, et al. Evaluation of the $GenoType^{(R)}$ MTBDRplus assay and identification of a rare mutation for improving MDR-TB detection. Int J Tuberc Lung Dis 2012;16:521-6. https://doi.org/10.5588/ijtld.11.0269
  20. Yadav RN, Singh BK, Sharma SK, Sharma R, Soneja M, Sreenivas V, et al. Comparative evaluation of GenoType MTBDRplus line probe assay with solid culture method in early diagnosis of multidrug resistant tuberculosis (MDR-TB) at a tertiary care centre in India. PLoS One 2013;5: e72036.
  21. Causse M, Ruiz P, Gutierrez JB, Vaquero M, Casal M. New $Anyplex^{TM}$ II MTB/MDR/XDR kit for detection of resistance mutations in M. tuberculosis cultures. Int J Tuberc Lung Dis 2015;19:1542-6. https://doi.org/10.5588/ijtld.15.0235
  22. Hristea A, Otelea D, Paraschiv S, Macri A, Baicus C, Moldovan O, et al. Detection of Mycobacterium tuberculosis resistance mutations to rifampin and isoniazid by real-time PCR. Indian J Med Microbiol 2010; 28:211-6. https://doi.org/10.4103/0255-0857.66474
  23. Chien JY, Chang TC, Chiu WY, Yu CJ, Hsueh PR. Performance assessment of the BluePoint MycoID plus kit for identification of Mycobacterium tuberculosis, including rifampin- and isoniazid-resistant isolates, and nontuberculous mycobacteria. PLoS One 2015;10:e0125016. https://doi.org/10.1371/journal.pone.0125016
  24. Bai Y, Wang Y, Shao C, Hao Y, Jin Y. GenoType MTBDRplus Assay for rapid detection of multidrug resistance in Mycobacterium tuberculosis: a meta-analysis. PLoS One 2016;11:e0150321. https://doi.org/10.1371/journal.pone.0150321

Cited by

  1. Comparison of Quantamatrix Multiplexed Assay Platform and GenoType MTBDR Assay Using Smear-Positive Sputum Specimens From Patients With Multidrug- Resistant/Extensively Drug-Resistant Tuberculosis in vol.10, pp.None, 2018, https://doi.org/10.3389/fmicb.2019.01075
  2. An ultra-sensitive “turn-off” fluorescent sensor for the trace detection of rifampicin based on glutathione-stabilized copper nanoclusters vol.145, pp.4, 2018, https://doi.org/10.1039/c9an01994d
  3. Evaluation of the QuantaMatrix Multiplexed Assay Platform for Molecular Diagnosis of Multidrug- and Extensively Drug-Resistant Tuberculosis Using Clinical Strains Isolated in Myanmar vol.40, pp.2, 2020, https://doi.org/10.3343/alm.2020.40.2.142
  4. Systematic Review of Mutations Associated with Isoniazid Resistance Points to Continuing Evolution and Subsequent Evasion of Molecular Detection, and Potential for Emergence of Multidrug Resistance in vol.65, pp.3, 2018, https://doi.org/10.1128/aac.02091-20
  5. False detection of rifampicin resistance using Xpert® MTB/RIF Ultra assay due to an A451V mutation in Mycobacterium tuberculosis vol.3, pp.3, 2018, https://doi.org/10.1093/jacamr/dlab101